Last reviewed · How we verify
Invokana Pill
Invokana Pill is a SGLT2 inhibitor Small molecule drug developed by AgelessRx. It is currently FDA-approved for Type 2 diabetes mellitus, Reduction of cardiovascular death and hospitalization for heart failure in patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors. Also known as: Canagliflozin.
Invokana (canagliflozin) inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose.
Invokana (canagliflozin) inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose. Used for Type 2 diabetes mellitus, Reduction of cardiovascular death and hospitalization for heart failure in patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors.
At a glance
| Generic name | Invokana Pill |
|---|---|
| Also known as | Canagliflozin |
| Sponsor | AgelessRx |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 (sodium-glucose cotransporter 2) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
SGLT2 inhibitors work by blocking the reabsorption of filtered glucose in the proximal tubule of the nephron, allowing excess glucose to be excreted in the urine. This mechanism is independent of insulin secretion or action, making it effective across different stages of type 2 diabetes. The drug also provides cardiovascular and renal protective benefits beyond glucose lowering.
Approved indications
- Type 2 diabetes mellitus
- Reduction of cardiovascular death and hospitalization for heart failure in patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Polyuria
- Hypotension
- Diabetic ketoacidosis
Key clinical trials
- Canagliflozin in Advanced Renal Disease With MRI Endpoints (PHASE2)
- The Efficacy and Tolerability of Canagliflozin in Healthy Individual (PHASE4)
- Canagliflozin-Mealtime Insulin Rescue (PHASE4)
- CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes (PHASE4)
- Treatment of Diabetes in Patients With Systolic Heart Failure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Invokana Pill CI brief — competitive landscape report
- Invokana Pill updates RSS · CI watch RSS
- AgelessRx portfolio CI
Frequently asked questions about Invokana Pill
What is Invokana Pill?
How does Invokana Pill work?
What is Invokana Pill used for?
Who makes Invokana Pill?
Is Invokana Pill also known as anything else?
What drug class is Invokana Pill in?
What development phase is Invokana Pill in?
What are the side effects of Invokana Pill?
What does Invokana Pill target?
Related
- Drug class: All SGLT2 inhibitor drugs
- Target: All drugs targeting SGLT2 (sodium-glucose cotransporter 2)
- Manufacturer: AgelessRx — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Indication: Drugs for Reduction of cardiovascular death and hospitalization for heart failure in patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors
- Also known as: Canagliflozin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing